MRNA
Moderna, Inc.
Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for Moderna, Inc..
Coverage
Latest: $145M (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | $1.86B |
| 2023Q2 | $344M |
| 2023Q3 | $1.83B |
| 2023Q4 | $2.81B |
| 2024Q1 | $167M |
| 2024Q2 | $241M |
| 2024Q3 | $1.86B |
| 2024Q4 | $966M |
| 2025Q1 | $108M |
| 2025Q2 | $142M |
| 2025Q3 | $1.02B |
| 2025Q4 | $678M |
| 2026Q1 | $389M |
| 2026Q2 | $145M |
Latest: -$1.97 (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | $0.19 |
| 2023Q2 | -$3.62 |
| 2023Q3 | -$9.53 |
| 2023Q4 | $0.56 |
| 2024Q1 | -$3.07 |
| 2024Q2 | -$3.33 |
| 2024Q3 | $0.03 |
| 2024Q4 | -$2.91 |
| 2025Q1 | -$2.52 |
| 2025Q2 | -$2.13 |
| 2025Q3 | -$0.51 |
| 2025Q4 | -$2.11 |
| 2026Q1 | -$3.40 |
| 2026Q2 | -$1.97 |
Latest: -$563M (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | -$1.34B |
| 2023Q2 | -$1.15B |
| 2023Q3 | -$1.74B |
| 2023Q4 | $402M |
| 2024Q1 | -$1.19B |
| 2024Q2 | -$1.46B |
| 2024Q3 | -$1.72B |
| 2024Q4 | $303M |
| 2025Q1 | -$1.15B |
| 2025Q2 | -$922M |
| 2025Q3 | -$880M |
| 2025Q4 | $891M |
| 2026Q1 | -$692M |
| 2026Q2 | -$563M |
Latest: -$11.20B (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | -$1.34B |
| 2023Q2 | -$2.49B |
| 2023Q3 | -$4.23B |
| 2023Q4 | -$3.83B |
| 2024Q1 | -$5.01B |
| 2024Q2 | -$6.47B |
| 2024Q3 | -$8.18B |
| 2024Q4 | -$7.88B |
| 2025Q1 | -$9.03B |
| 2025Q2 | -$9.96B |
| 2025Q3 | -$10.84B |
| 2025Q4 | -$9.95B |
| 2026Q1 | -$10.64B |
| 2026Q2 | -$11.20B |
Latest results
Company History
Launched by Flagship Pioneering to turn messenger RNA into a drug platform, on the premise that one manufacturing process could serve many diseases.
Priced its December 7, 2018 IPO at $23 a share, then the largest biotech IPO on record, still pre-revenue.
Spikevax received US emergency use authorisation in December 2020, taking the company from no approved product to global supply agreements within a year.
COVID vaccine demand carried full-year revenue to its high-water mark; revenue has fallen in every year since, to $1.9 billion in 2025.
The FDA approved mFLUSIVA on August 5, and on August 19 the Merck-partnered INTerpath-001 melanoma trial met its recurrence-free and distant metastasis-free survival endpoints.
Key Players
The CEO view — 5 podcasts, interviews & articles →
